SCHEMBL13498771

SCHEMBL13498771

CCN(CC)CCCNc1nccc2c(C)c3[nH]c4ccncc4c(=O)c3cc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 8/20 0.66
PDGFRA P16234 2/20 0.40
FGFR3 P22607 2/20 0.40
BRAF P15056 1/20 0.39
BRD4 O60885 1/20 0.39
ATAD2 Q6PL18 1/20 0.39
NQO1 P15559 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
PAX8 Q06710 1/20 0.39
NPSR1 Q6W5P4 3/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.37
TP53 P04637 2/20 0.37
TERT O14746 2/20 0.36
NSD2 O96028 1/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.36
NR3C1 P04150 2/20 0.36
POLB P06746 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pazelliptine SCHEMBL29376377 0.93 KIT (0.73) KITPDGFRAFGFR3BRAFNQO1
Pazelliptine SCHEMBL62441 0.93 KIT (0.73) KITPDGFRAFGFR3BRAFNQO1
Pazelliptine SCHEMBL1230910 0.92 KIT (0.72) KITPDGFRAFGFR3BRAFNQO1
Pazelliptine SCHEMBL1230570 0.91 KIT (0.71) KITPDGFRAFGFR3BRAFNQO1
SCHEMBL2311857 0.87 KIT (0.65) KITPDGFRAFGFR3ATAD2NPSR1
SCHEMBL12387163 0.84 KIT (0.61) KITPDGFRAFGFR3BRD4ATAD2
SCHEMBL2308783 0.83 KIT (0.59) KITPDGFRAFGFR3BRAFBRD4
SCHEMBL1065037 0.80 KIT (0.78) KITPDGFRAFGFR3BRAFNQO1
SCHEMBL2309766 0.80 KIT (1.00) KITPDGFRAFGFR3BRAFNQO1
SCHEMBL13596789 0.79 KIT (1.00) KITPDGFRAFGFR3BRD4ATAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041617-A1 Modulating mxa expression THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2010-02-18 US disclosed
US-20100041617-A1 Modulating mxa expression THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041617-A1 Modulating mxa expression IRF3, ZC3HAV1, MAVS KIT 3429/4885PDGFRA 2956/4885FGFR3 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.